Transgene Appoints Eric Quéméneur, PhD as Executive Vice President in Charge of Research & Development

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:

"I am very pleased to welcome Eric Quéméneur to Transgene. He has extensive experience effectively leading life sciences research teams and managing research collaborations. He is a wonderful addition to the Transgene senior management team and will be a great asset for the Company's development."
Transgene (Paris:TNG) (NYSE-Euronext: TNG) today announced the appointment of Eric Quéméneur, PhD as Executive Vice President in charge of Research and Development. In this position, he will lead all of the Company's research activities, from discovery through pre-clinical. Dr. Quéméneur is a member of Transgene's Management Committee.

Philippe Archinard, Chairman and Chief Executive Officer, said "I am very pleased to welcome Eric Quéméneur to Transgene. He has extensive experience effectively leading life sciences research teams and managing research collaborations. He is a wonderful addition to the Transgene senior management team and will be a great asset for the Company's development."

Eric Quéméneur has over 25 years of life sciences experience, including leading R&D efforts, building interdisciplinary teams and developing national and international partnerships. He joins Transgene from the French Atomic Energy Commission (CEA), where he worked for over 20 years in positions of increasing responsibility, most recently serving as Director, Research Programs and Industrial Partnerships in the Life Sciences Division. He has a strong scientific background in protein engineering, biomanufacturing technologies, toxicology, as well as bioanalytical development. He has authored nearly 80 articles published in international scientific journals. Dr. Quéméneur serves in a variety of advisory positions, including: Scientific Advisory Board member for recombinant vaccine production firm, Medicago Inc.; biotechnology business development advisor to Bertin Pharma and Bertin Technologies; and co-chair of the Radiobiology/Radiotoxicology programs at Areva. He has also been an administrator of CEA-I and ATI, two technology-oriented investment funds, and is a member of the international review panel for the Italian Ministry for Education, University and Research (MIUR). Dr. Quéméneur has a PhD in Biochemistry from the Claude Bernard University in Lyon, France.

About Transgene
Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize well-tolerated viruses with the goal of indirectly or directly killing infected or cancerous cells. The Company's two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at www.transgene.fr.

Société anonyme au capital de 87.964.029,39 € – R.C. Strasbourg B 317 540 581
400 boulevard Gonthier d'Andernach – Parc d'Innovation - CS80166 – 67405 ILLKIRCH GRAFFENSTADEN CEDEX (France)
Tél : + 33 3 88 27 91 00 - Fax : + 33 3 88 27 91 11

Contacts

Transgene
Elisabetta Castelli, +33 (0)3 88 27 91 21
Director Investor Relations
Laurie Doyle, +1 (339) 832 0752
Director Investor Relations US & Corporate Communications
[email protected]
or
MC Services
Raimund Gabriel, +49 89 210 228 30
[email protected]
Shaun Brown, +44 207 148 5998
[email protected]

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.